Oxidative stress in patients with COPD

Current Drug Targets

Volumn 12, Issue 4, 2011, Pages 469-477

  Loukides, Stelios ^a   Bakakos, Petros ^a   Kostikas, Konstantinos ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Antioxidants; Biomarkers; COPD; Oxidative stress; Pathophysiology

Indexed keywords

ACETYLCYSTEINE; ANTIOXIDANT; CARBOCISTEINE; CURCUMIN; ERDOSTEINE; FREE RADICAL; FUDOSTEINE; GLUCOCORTICOID; GLUTATHIONE; OXIDIZING AGENT; POLYPHENOL DERIVATIVE; REACTIVE OXYGEN METABOLITE; RESVERATROL;

ARTICLE; BRONCHOSPASM; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE MARKER; DISEASE PREDISPOSITION; ENVIRONMENTAL FACTOR; EXPIRED AIR; HUMAN; LUNG LAVAGE; OXIDATIVE STRESS; PATHOGENESIS; TREATMENT OUTCOME;

ANIMALS; ANTIOXIDANTS; BIOLOGICAL MARKERS; HUMANS; LUNG; OXIDATIVE STRESS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REACTIVE OXYGEN SPECIES;

EID: 79952761958     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/138945011794751573     Document Type: Article

References (105)

1. Rahman I, Biswas SK, Kode A. Oxidant and antioxidant balance in the airways and airway diseases. Eur J Pharmacol 2006; 533: 222-39.
2. Pryor WA, Dooley MM, Church DF. Mechanisms of cigarette smoke toxicity: the inactivation of human alpha-1-proteinase inhibitor by nitric oxide/isoprene mixtures in air. Chem Biol Interact 1985; 54: 171-83.
3. Rahman I, MacNee W. Role of oxidants/antioxidants in smoking- induced lung diseases. Free Radic Biol Med 1996; 21: 669-81.
4. Holland JA, Pritchard KA, Pappolla MA, Wolin MS, Rogers NJ, Stemerman MB. Bradykinin induces superoxide anion release from human endothelial cells. J Cell Physiol 1990; 143: 21-5.
5. Halliwell B. Free radicals, antioxidants, and human disease: curiosity, cause, or consequence? Lancet 1994; 344: 721-4.
6. Yao H, Yang SR, Kode A, et al. Redox regulation of lung inflammation: role of NADPH oxidase and NF-kappaB signalling. Biochem Soc Trans 2007; 35: 1151-5.
7. Kinnula VL. Production and degradation of oxygen metabolites during inflammatory states in the human lung. Curr Drug Targets Inflamm Allergy 2005; 4: 465-70.
8. Gutteridge JM, Quinlan GJ, Yamamoto Y. Hypothesis: are fatty acid patterns characteristic of essential fatty acid deficiency indicative of oxidative stress? Free Radic Res 1998; 28: 109-14.
9. Janssen LJ, Catalli A, Helli P. The pulmonary biology of isoprostanes. Antioxid Redox Signal 2005; 7: 244-55.
10. Richter C, Gogvadze V, Laffranchi R, et al. Oxidants in mitochondria: from physiology to diseases. Biochim Biophys Acta 1995; 1271: 67-74.
11. Sharafkhaneh A, Hanania NA, Kim V. Pathogenesis of emphysema: from the bench to the bedside. Proc Am Thorac Soc 2008; 5: 475-7.
12. Rahman I, MacNee W. Role of transcription factors in inflammatory lung diseases. Thorax 1998; 53: 601-12.
13. Reddy SP. The antioxidant response element and oxidative stress modifiers in airway diseases. Curr Mol Med 2008; 8: 376-83.
14. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007; 176: 532-55.
15. MacNee W, Tuder RM. New paradigms in the pathogenesis of chronic obstructive pulmonary disease I. Proc Am Thorac Soc 2009; 6: 527-31.
16. Smolonska J, Wijmenga C, Postma DS, Boezen HM. Meta- analyses on suspected chronic obstructive pulmonary disease genes: a summary of 20 years' research. Am J Respir Crit Care Med 2009; 180: 618-31.
17. Shapiro SD. Proteolysis in the lung. Eur Respir J Suppl 2003; 44: 30s-2s.
18. Shapiro SD, Ingenito EP. The pathogenesis of chronic obstructive pulmonary disease: advances in the past 100 years. Am J Respir Cell Mol Biol 2005; 32: 367-72.
19. Cavarra E, Lucattelli M, Gambelli F, et al. Human SLPI inactivation after cigarette smoke exposure in a new in vivo model of pulmonary oxidative stress. Am J Physiol Lung Cell Mol Physiol 2001; 281: L412-7.
20. Mak JC. Pathogenesis of COPD. Part II. Oxidative-antioxidative imbalance. Int J Tuberc Lung Dis 2008; 12: 368-74.
21. Rahman I, Adcock IM. Oxidative stress and redox regulation of lung inflammation in COPD. Eur Respir J 2006; 28: 219-42.
22. Cosio BG, Mann B, Ito K, et al. Histone acetylase and deacetylase activity in alveolar macrophages and blood mononocytes in asthma. Am J Respir Crit Care Med 2004; 170: 141-7.
23. Marwick JA, Kirkham PA, Stevenson CS, et al. Cigarette smoke alters chromatin remodeling and induces proinflammatory genes in rat lungs. Am J Respir Cell Mol Biol 2004; 31: 633-42.
24. Szulakowski P, Crowther AJ, Jimenez LA, et al. The effect of smoking on the transcriptional regulation of lung inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 174: 41-50.
25. Ito K, Ito M, Elliott WM, et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med 2005; 352: 1967-76.
26. Harman D. Free radical theory of aging: an update: increasing the functional life span. Ann N Y Acad Sci 2006; 1067: 10-21.
27. Ito K, Barnes PJ. COPD as a disease of accelerated lung aging. Chest 2009; 135: 173-80.
28. Nadeem A, Raj HG, Chhabra SK. Increased oxidative stress and altered levels of antioxidants in chronic obstructive pulmonary disease. Inflammation 2005; 29: 23-32.
29. Blum J, Fridovich I. Inactivation of glutathione peroxidase by superoxide radical. Arch Biochem Biophys 1985; 240: 500-8.
30. Hanta I, Kocabas A, Canacankatan N, Kuleci S, Seydaoglu G. Oxidant-antioxidant balance in patients with COPD. Lung 2006; 184: 51-5.
31. Daga MK, Chhabra R, Sharma B, Mishra TK. Effects of exogenous vitamin E supplementation on the levels of oxidants and antioxidants in chronic obstructive pulmonary disease. J Biosci 2003; 28: 7-11.
32. Forman HJ, Dickinson DA. Oxidative signaling and glutathione synthesis. Biofactors 2003; 17: 1-12.
33. Rahman I, Biswas SK, Jimenez LA, Torres M, Forman HJ. Glutathione, stress responses, and redox signaling in lung inflammation. Antioxid Redox Signal 2005; 7: 42-59.
34. Ghezzi P, Bonetto V, Fratelli M. Thiol-disulfide balance: from theconcept of oxidative stress to that of redox regulation. Antioxid Redox Signal 2005; 7: 964-72.
35. Cotgreave IA, Gerdes RG. Recent trends in glutathione biochemistry--glutathione-protein interactions: a molecular link between oxidative stress and cell proliferation? Biochem Biophys Res Commun 1998; 242: 1-9.
36. Das KC, Lewis-Molock Y, White CW. Activation of NF-kappa B and elevation of MnSOD gene expression by thiol reducing agents in lung adenocarcinoma (A549) cells. Am J Physiol 1995; 269: L588-602.
37. Rahman I, Mulier B, Gilmour PS, et al. Oxidant-mediated lung epithelial cell tolerance: the role of intracellular glutathione and nuclear factor-kappaB. Biochem Pharmacol 2001; 62: 787-94.
38. Rangasamy T, Cho CY, Thimmulappa RK, et al. Genetic ablation of Nrf2 enhances susceptibility to cigarette smoke-induced emphysema in mice. J Clin Invest 2004; 114: 1248-59.
39. Ishii Y, Itoh K, Morishima Y, et al. Transcription factor Nrf2 plays a pivotal role in protection against elastase-induced pulmonary inflammation and emphysema. J Immunol 2005; 175: 6968-75.
40. Sussan TE, Rangasamy T, Blake DJ, et al. Targeting Nrf2 with the triterpenoid CDDO-imidazolide attenuates cigarette smoke-induced emphysema and cardiac dysfunction in mice. Proc Natl Acad Sci USA 2009; 106: 250-5.
41. Noguera A, Batle S, Miralles C, et al. Enhanced neutrophil response in chronic obstructive pulmonary disease. Thorax 2001; 56: 432-7.
42. Rahman I, MacNee W. Regulation of redox glutathione levels and gene transcription in lung inflammation: therapeutic approaches. Free Radic Biol Med 2000; 28: 1405-20.
43. Papi A, Luppi F, Franco F, Fabbri LM. Pathophysiology of exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2006; 3: 245-51.
44. Cantin AM, North SL, Hubbard RC, Crystal RG. Normal alveolar epithelial lining fluid contains high levels of glutathione. J Appl Physiol 1987; 63: 152-7.
45. Drost EM, Skwarski KM, Sauleda J, et al. Oxidative stress and airway inflammation in severe exacerbations of COPD. Thorax 2005; 60: 293-300.
46. Duthie GG, Arthur JR, James WP. Effects of smoking and vitamin E on blood antioxidant status. Am J Clin Nutr 1991; 53: 1061S-3S.
47. Sadowska AM, Luyten C, Vints AM, Verbraecken J, Van Ranst D, De Backer WA. Systemic antioxidant defences during acute exacerbation of chronic obstructive pulmonary disease. Respirology 2006; 11: 741-7.
48. Calikoglu M, Unlu A, Tamer L, Ercan B, Bugdayci R, Atik U. The levels of serum vitamin C, malonyldialdehyde and erythrocyte reduced glutathione in chronic obstructive pulmonary disease and in healthy smokers. Clin Chem Lab Med 2002; 40: 1028-31.
49. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69: 89-95.
50. Horvath I, Hunt J, Barnes PJ, et al. Exhaled breath condensate: methodological recommendations and unresolved questions. Eur Respir J 2005; 26: 523-48.
51. Koutsokera A, Loukides S, Gourgoulianis KI, Kostikas K. Biomarkers in the exhaled breath condensate of healthy adults: mapping the path towards reference values. Curr Med Chem 2008; 15: 620-30.
52. Montuschi P. Exhaled breath condensate analysis in patients with COPD. Clin Chim Acta 2005; 356: 22-34.
53. Montuschi P, Barnes P, Roberts LJ, 2nd. Insights into oxidative stress: the isoprostanes. Curr Med Chem 2007; 14: 703-17.
54. Montuschi P, Barnes PJ, Roberts LJ, 2nd. Isoprostanes: markers and mediators of oxidative stress. FASEB J 2004; 18: 1791-800.
55. Montuschi P. Analysis of exhaled breath condensate in respiratory medicine: methodological aspects and potential clinical applications. Ther Adv Respir Dis 2007; 1: 5-23.
56. Dekhuijzen PN, Aben KK, Dekker I, et al. Increased exhalation of hydrogen peroxide in patients with stable and unstable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996; 154: 813-6.
57. Kostikas K, Papatheodorou G, Psathakis K, Panagou P, Loukides S. Oxidative stress in expired breath condensate of patients with COPD. Chest 2003; 124: 1373-80.
58. Gerritsen WB, Asin J, Zanen P, van den Bosch JM, Haas FJ. Markers of inflammation and oxidative stress in exacerbated chronic obstructive pulmonary disease patients. Respir Med 2005; 99: 84-90.
59. Montuschi P, Collins JV, Ciabattoni G, et al. Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. Am J Respir Crit Care Med 2000; 162: 1175-7.
60. Carpenter CT, Price PV, Christman BW. Exhaled breath condensate isoprostanes are elevated in patients with acute lung injury or ARDS. Chest 1998; 114: 1653-9.
61. Syslova K, Kacer P, Kuzma M, et al. Determination of 8-iso- prostaglandin F(2alpha) in exhaled breath condensate using combination of immunoseparation and LC-ESI-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 867: 8-14.
62. Borrill ZL, Roy K, Singh D. Exhaled breath condensate biomarkers in COPD. Eur Respir J 2008; 32: 472-86.
63. Van Hoydonck PG, Wuyts WA, Vanaudenaerde BM, Schouten EG, Dupont LJ, Temme EH. Quantitative analysis of 8-isoprostane and hydrogen peroxide in exhaled breath condensate. Eur Respir J 2004; 23: 189-92.
64. Carraro S, Cogo PE, Isak I, et al. EIA and GC-MS analysis of 8- isoprostane in EBC of children with problematic asthma. Eur Respir J 2009.
65. Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 1991; 11: 81-128.
66. Halliwell B. Lipid peroxidation, antioxidants and cardiovascular disease: how should we move forward? Cardiovasc Res 2000; 47: 410-8.
67. Corradi M, Rubinstein I, Andreoli R, et al. Aldehydes in exhaled breath condensate of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003; 167: 1380-6.
68. Osoata GO, Hanazawa T, Brindicci C, et al. Peroxynitrite elevation in exhaled breath condensate of COPD and its inhibition by fudosteine. Chest 2009; 135: 1513-20.
69. Paredi P, Kharitonov SA, Leak D, Ward S, Cramer D, Barnes PJ. Exhaled ethane, a marker of lipid peroxidation, is elevated in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 162: 369-73.
70. Brightling CE. Clinical applications of induced sputum. Chest 2006; 129: 1344-8.
71. Kinnula VL, Ilumets H, Myllarniemi M, Sovijarvi A, Rytila P. 8- Isoprostane as a marker of oxidative stress in nonsymptomatic cigarette smokers and COPD. Eur Respir J 2007; 29: 51-5.
72. Ichinose M, Sugiura H, Yamagata S, Koarai A, Shirato K. Increase in reactive nitrogen species production in chronic obstructive pulmonary disease airways. Am J Respir Crit Care Med 2000; 162: 701-6.
73. Kim JS, Hackley GH, Okamoto K, Rubin BK. Sputum processing for evaluation of inflammatory mediators. Pediatr Pulmonol 2001; 32: 152-8.
74. Metso T, Rytila P, Peterson C, Haahtela T. Granulocyte markers in induced sputum in patients with respiratory disorders and healthy persons obtained by two sputum-processing methods. Respir Med 2001; 95: 48-55.
75. Maestrelli P, El Messlemani AH, De Fina O, et al. Increased expression of heme oxygenase (HO)-1 in alveolar spaces and HO-2 in alveolar walls of smokers. Am J Respir Crit Care Med 2001; 164: 1508-13.
76. Nagai K, Betsuyaku T, Kondo T, Nasuhara Y, Nishimura M. Long term smoking with age builds up excessive oxidative stress in bronchoalveolar lavage fluid. Thorax 2006; 61: 496-502.
77. Jackson AS, Sandrini A, Campbell C, Chow S, Thomas PS, Yates DH. Comparison of biomarkers in exhaled breath condensate and bronchoalveolar lavage. Am J Respir Crit Care Med 2007; 175: 222-7.
78. Rahman I, Morrison D, Donaldson K, MacNee W. Systemic oxidative stress in asthma, COPD, and smokers. Am J Respir Crit Care Med 1996; 154: 1055-60.
79. Habib MP, Tank LJ, Lane LC, Garewal HS. Effect of vitamin E on exhaled ethane in cigarette smokers. Chest 1999; 115: 684-90.
80. Rautalahti M, Virtamo J, Haukka J, et al. The effect of alpha- tocopherol and beta-carotene supplementation on COPD symptoms. Am J Respir Crit Care Med 1997; 156: 1447-52.
81. Steinberg FM, Chait A. Antioxidant vitamin supplementation and lipid peroxidation in smokers. Am J Clin Nutr 1998; 68: 319-27.
82. Lykkesfeldt J, Christen S, Wallock LM, Chang HH, Jacob RA, Ames BN. Ascorbate is depleted by smoking and repleted by moderate supplementation: a study in male smokers and nonsmokers with matched dietary antioxidant intakes. Am J Clin Nutr 2000; 71: 530-6.
83. Grievink L, Smit HA, Ocke MC, van 't Veer P, Kromhout D. Dietary intake of antioxidant (pro)-vitamins, respiratory symptoms and pulmonary function: the MORGEN study. Thorax 1998; 53: 166-71.
84. Rahman I, MacNee W. Lung glutathione and oxidative stress: implications in cigarette smoke-induced airway disease. Am J Physiol 1999; 277: L1067-88.
85. Rahman I, MacNee W. Oxidative stress and regulation of glutathione in lung inflammation. Eur Respir J 2000; 16: 534-54.
86. Bridgeman MM, Marsden M, Selby C, Morrison D, MacNee W. Effect of N-acetyl cysteine on the concentrations of thiols in plasma, bronchoalveolar lavage fluid, and lung tissue. Thorax 1994; 49: 670-5.
87. Dekhuijzen PN, van Beurden WJ. The role for N-acetylcysteine in the management of COPD. Int J Chron Obstruct Pulmon Dis 2006; 1: 99-106.
88. Zuin R, Palamidese A, Negrin R, Catozzo L, Scarda A, Balbinot M. High-dose N-acetylcysteine in patients with exacerbations of chronic obstructive pulmonary disease. Clin Drug Investig 2005; 25: 401-8.
89. Kasielski M, Nowak D. Long-term administration of N- acetylcysteine decreases hydrogen peroxide exhalation in subjects with chronic obstructive pulmonary disease. Respir Med 2001; 95: 448-56.
90. De Benedetto F, Aceto A, Dragani B, et al. Long-term oral N- acetylcysteine reduces exhaled hydrogen peroxide in stable COPD. Pulm Pharmacol Ther 2005; 18: 41-7.
91. Decramer M, Rutten-van Molken M, Dekhuijzen PN, et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet 2005; 365: 1552-60.
92. Sutherland ER, Crapo JD, Bowler RP. N-acetylcysteine and exacerbations of chronic obstructive pulmonary disease. COPD 2006; 3: 195-202.
93. Moretti M, Bottrighi P, Dallari R, et al. The effect of long-term treatment with erdosteine on chronic obstructive pulmonary disease: the EQUALIFE Study. Drugs Exp Clin Res 2004; 30: 143-52.
94. Zheng JP, Kang J, Huang SG, et al. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study. Lancet 2008; 371: 2013-8.
95. Arts IC, Hollman PC. Polyphenols and disease risk in epidemiologic studies. Am J Clin Nutr 2005; 81: 317S-25S.
96. Tabak C, Arts IC, Smit HA, Heederik D, Kromhout D. Chronic obstructive pulmonary disease and intake of catechins, flavonols, and flavones: the MORGEN Study. Am J Respir Crit Care Med 2001; 164: 61-4.
97. Santus P, Sola A, Carlucci P, et al. Lipid peroxidation and 5- lipoxygenase activity in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 171: 838-43.
98. Culpitt SV, Rogers DF, Fenwick PS, et al. Inhibition by red wine extract, resveratrol, of cytokine release by alveolar macrophages in COPD. Thorax 2003; 58: 942-6.
99. Kode A, Rajendrasozhan S, Caito S, Yang SR, Megson IL, Rahman I. Resveratrol induces glutathione synthesis by activation of Nrf2 and protects against cigarette smoke-mediated oxidative stress in human lung epithelial cells. Am J Physiol Lung Cell Mol Physiol 2008; 294: L478-88.
100. Biswas SK, McClure D, Jimenez LA, Megson IL, Rahman I. Curcumin induces glutathione biosynthesis and inhibits NF-kappaB activation and interleukin-8 release in alveolar epithelial cells: mechanism of free radical scavenging activity. Antioxid Redox Signal 2005; 7: 32-41.
101. Meja KK, Rajendrasozhan S, Adenuga D, et al. Curcumin restores corticosteroid function in monocytes exposed to oxidants by maintaining HDAC2. Am J Respir Cell Mol Biol 2008; 39: 312-23.
102. Filomeni G, Rotilio G, Ciriolo MR. Cell signalling and the glutathione redox system. Biochem Pharmacol 2002; 64: 1057-64.
103. Smith KR, Uyeminami DL, Kodavanti UP, Crapo JD, Chang LY, Pinkerton KE. Inhibition of tobacco smoke-induced lung inflammation by a catalytic antioxidant. Free Radic Biol Med 2002; 33: 1106-14.
104. Jozsef L, Filep JG. Selenium-containing compounds attenuate peroxynitrite-mediated NF-kappaB and AP-1 activation and interleukin-8 gene and protein expression in human leukocytes. Free Radic Biol Med 2003; 35: 1018-27.
105. Thimmulappa RK, Mai KH, Srisuma S, Kensler TW, Yamamoto M, Biswal S. Identification of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray. Cancer Res 2002; 62: 5196-203.